Twitter Beğeni Hilesi

This group has previously published heterobifunctional degraders apparently based on the N-end rule, and here they add to the tally. pubs.acs.org/doi/abs/10.102…

Strangely you’re not going to find my high school job working part-time as a cook at Pizza Hut or my college job logging a few hours a week at the library computer lab on my CV — because neither are relevant professional experience

Have been meaning to highlight this paper on macrolones for a while now — hitting bacteria on 2 targets to reduce resistance. While almost certainly not proximity inducers, there’s easy parallels between their structures and heterobifunctional degraders. nature.com/articles/s4158…

Live footage of me after my college freshman announced after 1.5 weeks away that he’s going into NYC by himself to see a matinee on Broadway It’s fine - really

I don’t have a blogging track record as long as Derek’s, but I’ve certainly accumulated my share of misses in 22 years of doing drug discovery. Might be fun to tally them up.

Biggest risk of being wrong in the future: maybe all of the AI drug discovery proponents will be right in another 15-20 years and everything I’ve said will look foolish. It’s hard to predict the trajectory of that kind of technology. Less hard to be real about where it is today.

I started writing a post about this for the blog and it’s gonna be a banger!

Preview: one of my three biggest misses in 22 years in pharma was… KRAS and that’s the smallest one that I missed

Have done this drive, with detour to the north to see the world’s largest ball of twine in Cawker City, KS and can confirm. Although pushing through the Nebraska panhandle is right up there

After all these years, it’s really amazing how one of the more important skills I possess is the ability to count to 5 and 6

Graham’s ‘founder mode’ seems nebulous. I also wonder how transferable it is to biotech, and what examples we can point to. Many founders are academics with outstanding ideas, but no real world expertise reducing to practice. They need teams of seasoned professionals to execute.

MAGE-A3 degraders from the Craig Crews lab. Nice example of how ligand discovery with DEL screening can mesh into degrader workflows. pubs.acs.org/doi/10.1021/ja…

We welcomed Rebecca Surran from News12CT to #Arvinas for an exclusive look at our labs! She joined CSO Angela Cacace to discuss our innovative research & commitment to developing new treatments for life-altering diseases. Check it out: rb.gy/r9t4qo #TeamArvinas #TPD

New MLK3 degraders. pubs.acs.org/doi/10.1021/ac…

Today in Neighborhood Nature: chipmunk darts across the street in front of my car, narrowly misses getting hit… then immediately gets pounced on by a hawk after crossing the street. Game over

New MLKL degraders. Will note that the covalent handle abrogates potential turnover - these become stoichiometric. But still seem to degrade reasonably. pubs.acs.org/doi/10.1021/ac…

I’ve been fascinated since the word go by this developing story from the Woo lab regarding C-terminal cyclic Asn and Gln residues as a natural CRBN-mediated protein quality control mechanism. Here’s the next installment. biorxiv.org/content/10.110…

Fake it til you make it, fortune cookie style 🥠